Bright Minds Biosciences (DRUG) Payables (2020 - 2026)
Bright Minds Biosciences' (DRUG) quarterly Payables came in at $2.7 million in Q1 2026, up 600.5% YoY from $390423.8 in Q1 2025, and up 155.22% on a QoQ basis from $1.1 million in Q4 2025.
Bright Minds Biosciences (DRUG) Payables (2020 - 2026) Analysis & Trends
Bright Minds Biosciences (DRUG) has 7 years of Payables data on file, last reported at $2.7 million in Q1 2026.
- Quarterly Payables rose 600.5% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 600.5% YoY) and the FY2025 annual result came in at $1.6 million, up 447.45% from the prior year.
- Payables advanced to $2.7 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Payables ranged from a high of $2.7 million in Q1 2026 to a low of $120354.5 in Q2 2024.
- A 5-year average of $701854.8 and a median of $478983.7 in 2023 frame the typical range for Payables.
- Annual changes were most pronounced in 2022 — Payables jumped 133240.8% — and 2023, when it slumped 85.64%.
- Tracing DRUG's Payables over 5 years: stood at $337544.0 in 2022, then surged by 74.0% to $587332.4 in 2023, then slumped by 52.61% to $278362.9 in 2024, then soared by 284.97% to $1.1 million in 2025, then surged by 155.22% to $2.7 million in 2026.
- The last three Payables figures came in at $2.7 million (Q1 2026), $1.1 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Bright Minds Biosciences | 733.05 Mn | 733.05 Mn | - | 2.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.73 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 380,200.31 |
| Mar 31, 2025 | 390,423.76 |
| Dec 31, 2024 | 278,362.95 |
| Sep 30, 2024 | 298,754.45 |
| Jun 30, 2024 | 120,354.51 |
| Mar 31, 2024 | 601,894.63 |
| Dec 31, 2023 | 587,332.40 |
| Sep 30, 2023 | 154,636.61 |
| Jun 30, 2023 | 478,983.69 |
| Mar 31, 2023 | 689,544.21 |
| Dec 31, 2022 | 337,544.03 |
| Sep 30, 2022 | 1.08 Mn |
| Jun 30, 2022 | 302,225.28 |
| Mar 31, 2022 | 792,250.41 |
| Dec 31, 2021 | 388,414.17 |
| Sep 30, 2021 | 507,288.34 |
| Jun 30, 2021 | 262,655.38 |